`
`LINGUAL
`
`CROSSLINGUAL, LLC
`3736 Fallon Road, Suite 226
`Dublin, CA 94568
`Tel: 206-851-7932
`hr@clingual.com
`
`AFFIDAVIT OF TRANSLATION
`
`I, Alan F. Siegrist, of CROSSLINGUAL, LLC, hereby declare that:
`I am fluent in Japanese and English.
`1.
`2.
`I am an active member of the American Translators Association and a Certified
`Translator of Japanese to English.
`3. The English translation attached to this declaration is an accurate and correct
`translation of the following document, attached hereto:
`2000.5 - 1st Edition [Bronuck Package Insert]
`I declare that the foregoing is true and correct to the best of my knowledge.
`
`Executed on October 29, 2015
`
`Alan F. Siegrist, CT
`CROSSLINGUAL, LLC
`ATA Member No. 31889
`Certification #63788
`
`Veity at www.atanet.org/Veity
`
`A notary public or other officer completing this certificate verifies only the identity of the individual who signed the
`documents to which this certificate are attached, and not the truthfulness, accuracy, or validity of that document.
`
`State of California, County of Gl\-lnt Gsx
`
`I
`I . I '
`l!cve-iti\~ Wd-<r= [3DJJ~
`
`on Cltok ~1 c?ol5
`personally appeare: a1 ql) F s;-~l' s·t
`
`beforeme,
`
`who proved to me on the basis of satisfactory
`evidence to be the person whose name IS subscribed to the within instrument and acknowledged to me
`that he executed the same in his authorized capacity, and that by his signature on the instrument the
`person, or the entity upon behalf of which the person acted, executed the instrument.
`
`1 certify under PENALTY OF PERJURY under the laws ofthe State of California that the foregoing
`paragraph is true and correct.
`
`Witness my hand and official seal.
`
`Page 1 of 5
`
`SENJU EXHIBIT 2111
`LUPIN v. SENJU
`IPR2015-01099
`
`
`
`May 2000 – Created (New Format, First Edition)
`
`Storage Method: Room temperature storage
`Expiration:
`To be used by the expiration date displayed on the exterior package
`(even before expiration, to be used promptly after opening).
`
`Japan Standard Commodity Classification No. 871319
`Approval No.
`21200AMZ00168
`Drug price listed
`May 2000
`Sales initiation
`July 2000
`International origin
`July 1997
`
`
`
`Non-steroidal anti-inflammatory ophthalmic agent
`Designated Prescription Drug BRONUCK® OPHTHALMIC SOLUTION
`Bromfenac sodium hydrate ophthalmic solution
`
`
`
`
`
`The following adverse effects were observed in the foregoing
`study.
`0.1% to less than 5%
`
`Ocular† Blepharitis, conjunctival hyperemia, stinging, ocular pain
`(temporary), corneal inflammation, corneal epithelial abrasion,
`superficial punctate keratitis, follicular conjunctivitis, pruritus,
`and burning sensation (eyelids)
`†When manifested, administration is suspended.
`3. Administration to Pregnant, Parturient, and Nursing
`Women
`Administration is to be conducted to pregnant woman or
`women who may have conceived and to women who are
`nursing only when it is judged that the benefits of treatment
`outweigh the risks.
`(The safety of administration during pregnancy and lactation
`has not been established.)
`4. Administration to Children
`Safety relative to children has not been established (there is
`little experience with use).
`5. Cautions for Use
`(1) Administration route: only to be used for ocular instillation
`(2) At time of administration: during ocular instillation, take
`care so that the lip of the container does not directly contact
`the eye.
`[Pharmacokinetics]
`(Reference)
`Intraocular Migration <rabbits>1)
`In testing wherein ocular instillation of 0.05 mL of 0.1% 14C-
`bromfenac sodium hydrate ophthalmic solution was conducted
`once a day is both eyes of rabbits, and radioactivity was
`measured after 15 minutes, 30 minutes, and 1, 2, 4, 8, 32, 24,
`48, and 72 hours, elevated values were observed in the cornea,
`conjunctiva, and anterior sclera.
`At 72 hours after ocular instillation, all ocular tissue except
`for the lens was below the detection limit (0.1 ng eq./g or ml).
`
`Cornea
`Conjunctiva
`Anterior sclera
`Anterior vitreous humor
`Blood
`Below detection limit
`
`Hours after ocular instillation
`
`(hours)
`
`
`Bromfenac sodium hydrate concentration
`
`
`
`[Contraindications (do not administer to the following
`patients)]
`Patients with a previous history of hypersensitivity to the
`ingredients of this drug
`[Composition / Properties]
`Ingredients / content
`Bromfenac sodium hydrate 1 mg
`(in 1 ml)
`Boric acid, borax, dry sodium sulfite, sodium
`edetate, povidone, polysorbate 80,
`benzalkonium chloride
`Aqueous ophthalmic solution
`Clear yellow
`8.0–8.6
`Aseptic preparation
`
`Additives
`
`Form of drug
`Color
`pH
`Other
`[Efficacy / Effects]
`Symptomatic treatment of inflammatory ailments of the
`external eye and anterior eye (blepharitis, conjunctivitis,
`scleritis
`(including
`episcleritis),
`and
`postoperative
`inflammation)
`[Usage / Dosage]
`Ordinarily, 1-2 drops per administration, and 2 ocular
`instillations per day.
`[Cautions for Use]
`1. Important Basic Cautions
`(1) Keeping in mind that treatment by this drug is symptomatic
`treatment rather than causal treatment, and that it is
`reported that serious liver damage (including death) has
`been observed
`in patients subjected
`to
`long-term
`administration of 1 month or more with the oral agent of
`bromfenac sodium, continuous administration for 4 weeks
`or more is not conducted in principle. Although the
`aforementioned adverse effects observed with the foreign
`oral agent were due to long-term administration exceeding
`the approved usage and dosage, sales have been voluntarily
`suspended.
`(2) As there is risk that eye infection may become subclinical,
`in case of use on inflammation resulting from infection,
`administration is to be conducted carefully with adequate
`observation.
`2. Adverse Effects
`At the time of approval, adverse effects had been observed in
`16 out of a total of 423 cases (3.78%).
`With respect to the content of adverse effects, there were
`3 cases of blepharitis (0.71%), 3 cases of conjunctival
`hyperemia (0.71%), 3 cases of stinging (0.71%), 3 cases of
`ocular pain
`(temporary)
`(0.71%), 2 cases of corneal
`inflammation (0.47%), 1 case of conical epithelial abrasion
`(0.24%), 1 case of superficial punctate keratitis (0.24%), 1 case
`of follicular conjunctivitis (0.24%), 1 case of pruritus (0.24%),
`and l case of burning sensation (eyelids) (0.24%) (at the time of
`approval).
`
`Page 2 of 5
`
`
`
`[Principal Literature]
`1) Mitsuyoshi Isaka et al.: Pharmacokinetics, 14 (1) 32, 1999.
`2) Takahiro Ogawa et al.: Journal of Japan Ophthalmology Society, 99, 406, 1995.
`[Contact for Requesting Literature]
`Scientific Information Department
`Senju Pharmaceutical Co., Ltd.
`5-8, Hirano-machi 2-chome, Chuo-ku, Osaka-shi, Osaka
`
`Marketed by: Takeda Pharmaceutical Co., Ltd.
`
`1-1, Dosho-machi 4-chome,
`
`Chuo-ku, Osaka
`
`Package 00-009
`
`
`
`
`
`
`
`
`
`Efficacy rate (%) and
`effectiveness
`66.7 (6/9)
`63.2 (60/95)
`63.6 (7/11)
`86.4 (152/176)
`77.3 (225/291)
`
`relative
`
`to
`
`experimental
`
`[Clinical Results]
`A summary of results with respect to 291 cases including
`double-blind comparative testing are shown in the table.
`For the most part, daily dosage and administration period
`were 1 drop per administration and 2 administrations per day
`over a 2-week period.
`Table. Clinical Effects by Ailment
`Name of ailment
`Blepharitis
`Conjunctivitis
`Scleritis (including episcleritis)
`Postoperative inflammation
`Total
`[Pharmacoefficacy and Pharmacology]
`1. Pharmacological Action
`(1) Anti-inflammatory
`action
`conjunctival chemosis in rats2)
`It was observed that Bronuck ophthalmic solution exhibited
`anti-inflammatory action relative to experimental acute
`conjunctival chemosis in rats induced by arachidonic acid
`and carageenin.
`(2) Inhibitory effects relative to increases in aqueous humor
`protein concentration in rabbits after anterior chamber
`paracentesis or after laser irradiation2)
`It was observed that Bronuck ophthalmic solution almost
`completely inhibited increases in aqueous humor protein
`concentration in rabbits after anterior chamber paracentesis
`or after laser irradiation.
`2. Mechanism of Action
`In tests using rabbit iris-ciliary bodies2) and bovine seminal
`vesicles, it was confirmed that inhibitory action was exhibited
`against production of prostaglandin inflammatory mediators via
`cyclooxygenase (in vitro).
`[Physicochemical Findings Relative to Active Ingredients]
`Generic name:
`Bromfenac Sodium Hydrate (JAN)
`Chemical name:
`sodium 2-amino-3-(4-bromobenzoyl)
`phenylacetate sesquihydrate
`Molecular formula: C15H11BrNNaO3 · 1½ H2O
`Molecular weight: 383.17
`Structural formula:
`
`
`Properties:
`
`
`
`
`Bromfenac Sodium Hydrate is an odorless
`crystalline powder of yellow-orange color.
`It is freely soluble in water, soluble in
`methanol, slightly soluble in ethanol
`anhydride, and practically insoluble in
`acetonitrile or ether.
`
`[Packaging]
`5 mL × 10, 5 mL × 50
`
`
`
` Manufactured by: Senju Pharmaceutical Co., Ltd.
`
`
`5-8, Hirano-machi 2-chome,
`
`
`Chuo-ku, Osaka
`
`Page 3 of 5
`
`
`
`i~ : ~~ iluH!IW
`lti'
`f!l.!JIJJUJI!R: 7Hi'ii:J(,J~O)f!J.!JIJJY!Ia~JJ..H:f!l.!IIIT .Q.:: t (f!l.!IIIJmHJJ..J"C:"
`<i?-?-ct, IJfJH1Ht.illi'\-'7H:f!l.!Jli-9Z>.:t) o
`
`. -
`'" .~. 1l'f ~}
`:»J {lUi JlX .r&.
`ll&?'Cml~
`1~1 ~ .~ '1:
`
`2J200Ai\IZOO J68
`2000{1' 5 JJ
`2000~ 7 F.l
`1997{1: 7 J J
`
`--
`
`o.1- 5 %;¥:r~
`u~ m ~~~~, t~ J~ Jelfn., JlliJif( ~, IUHII'i[ - ~t1L
`fiJ ~BiUW, f1J ~~ ~&:!FIJ~ , .. .':(~x:&~ifJ ~
`tX. ~~ i&t JY&.' fAH$~, ~~ [ IIR~ J
`~ '
`i lJ 7E .£)1. Lt.: t)h~ ~.: ti, 1'i 7· ~ rp .II:~~ .:: t o
`3. ~~, /¥~ , ~~L~~"'-<7)~4
`tt-l~~XIitlf~ L.. ~~'~ 1if)'jgf.l~~~~uA&U~$Lrp~
`~A~~~-t~~~tl~~-tt~~~~C:fi~~tt
`~.tJJrfr~.:~.;z...& 7-~ ~.:: C: o
`CH~~r .&U!f:fLrr ~& 'J-t:m~-t ~'ti.'~t£1i1i(Jut t... -c"'
`;>j:~' o ]
`4. 'H'C~"'-<7)~4
`,J,~n~I.:M~ ~ 1-C~t1ti1i(JUt L ~ "' ij: ~' ( {.,eJlH:U.Ril'1-'
`;>j:l.-') o
`5. )MffjJ:<7)5i.
`(1 )~4ft~ : .¢.i:f~JJH.:~.;z,..f~fH~ ~.::t o
`(2)~ 4 ~ : ,¢.i:IIR~ t ~, ~~~7\::tifilil' Jli~ 1=1 t.:f!!l!tt
`ij: "' J: 1 ~=u:~:-t ~ .:: e: o
`
`[~!li.ll.t.J~]
`(~ ~-)
`DHI*I~fr ( 7 -tf'.:¥)"
`7 -tf'.:¥0)tJiiliUH:O.J%"C·70 J.... 7 :r.. -J-7 -J- r 1) 7 J.... 4<-1'11~ .'.'XIIJiilt
`0.05mLI!:- J liiiJ.'.UIR L, 15, 305}, L 2, 4, 8, 12, 24, 48, 721~
`~-~~Mmtti!:--~L~~~-c-~,~m,M~&UOOM·~~
`
`.'.'1: IU~ ft: 72 II~ P.O "t'" li , 4< ~~1d-f>: \!:- ~-?t < -9"' -c 0) IIR ttl~ -c- ~ ll\ llt! W
`(O.Jng eq./g or mLH:I. f"t'"<l? -? t.:o
`
`:ti!J All
`-
`o---o : fa All
`- - : ffi!Bil~Bll
`o---o : ffilljf7.1<
`-:an illi
`\\\\\\\\\ : ~l±li!!H'I-J..~'F
`n=3
`
`(ng eq./g or ml)
`104
`
`-;)' 103
`0
`b.
`7
`J:
`7 102
`':7
`7
`t-
`
`1) .,
`b. i i.l
`
`!.It
`
`1
`
`J£'l}. ~1.~:
`(1mL•I 1)
`
`i.~}JIJ~
`
`7'0 J.... 7 :r.. -t 7 -t r 'J 7 J.... 4<-1'11~ 1 mg
`
`*7~-*7D, ~-~~~-tr~7J....,~
`7 r~-t r 1J 7J...., ;y.~:: r·::.-, ;f-'1) 'J Jv~-
`1-80, ~..(fl::~/-!fJv:J.=.7J....
`
`~I Jf~
`
`4<1'1:/XIIJ{~Ij
`
`1g
`
`pH
`{'O)fl!!
`
`&~iQIYJ
`
`8.0-8.6
`
`!!!lii!i~~J
`
`[~tm · ~~1
`~me&u~mM~~~tt~m~M~•~ cm~~ - Mm
`~, 5nlJJ~ ~ u~3nt ~~~ ~ ~ 1H.r) , .w11t: ~ffEJ
`
`[ffl~ii. ffl~]
`~~, 1 @1-2~, 1U2@~m~~ o
`
`[ f.fffll: O)~.ii\]
`1. ·~ t.!:~*tr:l5i~
`(' l4s::~¥H: J:: ~ rrtftW:JJ:l!Nn.tr.k"t" ti ij: < MfiUJH~-z" ~ ~
`.:: e: ~.:'\W~L, ~t.:, ~oo~=.t:>~,-c 7"ah7J..T
`~7~ ~ 7h~ftUM~1~ft~t~M&~L~~
`:tr ~=m:m ij: JJflif,1~;: (1Ec ~-a-u-) tJt.N!.&? G nt.: e: ~~
`~~~~~-c.", ~me:L~4~~~~~~M&4~
`~1-b;>j:~,.:: C: o ;>j:.t:;, :Y~OO~*fii ~H.:~&? Gnt.:~
`ilc ~ li\1Jf1= ffH i 11< ~ ~ JIH£ · Jfl iJ: ~ Ali ;{. t.: ~ J~J & 41.:
`J:: ~ 'b~"(·~~i)t, LI.::J:.I'J9~.:JIOC%~'1 1 JJ~. l.-~1.-'~ o
`( 2)1~ ~~~~~1'l/1i1t 1~ ~ ~ .t:>-fttil{~ ~ ~-r:·, ~~~
`1.: J:: ~ ~ff£ I.:M L.. ~ ffl "' ~ t),}ftl.: ti Wl~ ~ t-5t~.:~=r
`"', ti'i:'IH.:& 7-~ ~.::t o
`2.11Jf'Fffl
`;i<~&-~ -c~r,gff£fyU423~U '1 1 16f9!1 (3.7896) t: /JIIfi:=JIJ iJt~&'J
`G hf.: o
`1i1iJ11=ffl r''J?Cf:ti, IIRI~~ 3 ft~ (0.71%), ~f)J~JC1111 3 ft (0.71
`%) , JllU~~ 31'H0.71 %) , l~frfi [ -~ttJ 31'H0.71 %) , ifJ
`~~~11l 214 (0.4796), fiJ ~~~&:~IJ~ 1 f'H0.24%), ... ~~:!**
`Jr1ftl I&~ 1 14 (0.24%)' *fi~Wfilt\tll?! 1 14 (0.24%), fjtift~ 1
`f'H0.24%), ?.M&[~~J 1 ft(0.24%)"t"~-:> t.: (7"'~~)o
`
`Page 4 of 5
`
`
`
`[~'l;f;ii;Jilt.l
`=:ili:m ~Jtif<I<MP.«""!!I< >:<-str291 fill 1:-> '' -c O)Jll(;li'Hilil'li!liJ'<O) t
`;13 ~ <.',;, <> 0
`t;:;t;, I Bllt-':i-:!1!, .Yi:-':i-l!llliUii:k:l\11~/n'J liTI I i,li, I B 2llli, 2 j!\1
`I:U <.' <!; <> o
`'ii.. !9i.\I.\ZUI!I.ii1<3\'Jr!R
`
`* .\1.\ r.
`
`IIR Ill> iii:
`*11 Iii! iii:
`'iJil IJ>l iii:
`(J:'iJil[J;[i!i:Hstr l
`Aii£!!i:!i£
`Ot
`
`A
`D
`
`.
`
`[::E~Sl:ili!:l
`I) Jf;l!JtJ't.il!.J& : ll!!!fPJWh!!!l. 14(1), 32, 1999.
`2) 'J•i"ft'tliiffil : E1 *III!H$4:1~~~.!;. 99, 406, 1995.
`
`[Sl:ili!:~i!J}J(stl
`HJ!i1ll!!f.f<>t4:1t±
`'f-il'itMilftll
`'i' 541-0046 :klliTii>l'*iR 'l'ffitPIT= TEl 51il' 8 iJ'
`
`1"13\'JJ$ (%) fil\'!Jt.U:
`66.7 ( 61 9)
`
`·.
`
`63.2 ( 60/ 95)
`
`63.6 ( 71 II)
`
`86.4 (152/176)
`
`77.3 (225/291)
`
`[~)1}]~!1]
`1. ll!!!!J!f'i'lll
`I 1 )7 ., ~ l!<~f(.J*IlJJl!i'J!!II:;t;t-; ~ ml!t!i£1'i'lll"
`7't17?7.~1ili!l'li7·J H:;Sit<>77'\'-r:.-J'i!1, '/J7'T=(cid:173)
`:.-I: J: <> ;I!JII((J'J.\l),f£*1111i!ii'JJl!I:M L.tJi:i!i:!iE1'i'lll >:!c>Fi';: t iJ'
`iil(IOJ?;[L ""C<•<>o
`I 2)'/ -if 'I"Wi~:ll';llHitR !i L.- -"if- ff~MWO) J;< >l< ll! s ~lir!ll~o 1:
`;t;t-; ~li1J$U!lhll!"
`7'o-t ., 7 tii!Ri!l'li? "'''fl:;t;lt <> Ji'ul»!l<WUI£XIi v-"i'(cid:173)
`w.IMI£0)ijfJl<!IH3iB!IlVi'lhll >:< ll' li'i0:£:1:!fiJIDUi' <>;: t iJ'i\!!lb
`G;I'L ""C<•<>o
`2. 1'1' llll!!!ff'
`? "'''f!l!l::liJ'i':lllW' .&i:J'? i-'flifi: >:<Ill'' to""iii<I:;S '' -c, i-' 7
`t1~'\'-i-''T7-~>:i'cki'<>7'tJA9~7;.-y;.-*O)i!i;!JE~71
`.:rc- 9 -!Efoc!fll~iH'f.lll >:!c>Fi';: t iJ'f>li!£ ~ ;11. -c ''<>(in vitro) o
`
`[~)I}]Jilt7.l'l<:: ll!!9 :Q !lft~l)'g9<D~l
`-fii'. : 7'o h 7, 7 7 7 r 1J? h Jl<tn!fn
`(Bromfenac Sodium Hydrate) (JAN]
`1t~:t : sodium 2-amino-3- (4-bromobenzoyl) phenylacetate
`sesquihydrate
`7.1-.::Y-P:; : CtsHnBrNNa03 · 1 t HzO
`5)-'flll: : 383.17
`Wlili>t: Br-0-~-Q'
`
`H2N
`
`CH2C02Na · ll/2H20
`
`1'1;
`
`;JR: 7't1h7,777r 1J?h Jl<tD!fnl;l, ll'ifS-Jl!fgO)*If,lJ.
`!iO);j;)*"t', (:;SH;li;:<•o
`Jl<~Mit.i'(, ~9/-•~••Mit•i'<,.Jl<.:rc
`1/-·~•~~<<, 7~r=-r0•x~.:rc-~·~
`IJ' /:_ /v /:'j!'flt ;/j: <•o
`
`ill
`[~
`5mL x 10, 5mL x 50
`
`~~ =f lij ~ ~ l!li J'1: ~ u
`*ll<T[i<i'~IR 'I'IDfffl!= T §511'i81Jo
`
`P&7C
`
`JEt EE 5i ~I·~** it~*±·
`*ll<lli'I'~IRil!l~mnrnr 13 Iifi I-~·
`
`'21.00-01)9
`
`Page 5 of 5